Wnt/frizzled signaling in hepatocellular carcinoma

被引:131
作者
Lee, HC
Kim, M
Wands, JR [1 ]
机构
[1] Rhode Isl Hosp, Liver Res Ctr, Providence, RI 02903 USA
[2] Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA
[3] Brown Univ, Sch Med, Providence, RI 02912 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2006年 / 11卷
关键词
hepatocellular carcinoma; Wnt signaling; frizzled receptors; beta-catenin; review;
D O I
10.2741/1933
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Wnt/Frizzled (FZD) signaling cascade is important for cell fate determination during embryonic development as well as maintaining tissue homeostasis in the adult. In addition to these physiologic roles, studies have shown that deregulation of Wnt/FZD signaling occurs during carcinogenesis. As an example, over 90% of the colorectal cancers have mutations in adenomatous polyposis coli (APC) or beta-catenin genes. In addition, hepatocellular carcinoma (HCC) is another tumor with frequent aberrant activation of beta-catenin signaling. Nuclear and/or cellular beta-catenin accumulation, a hallmark of the activated canonical Wnt/FZD signaling, has been observed in 33-67% of tumors. However, mutations of APC and/or beta-catenin genes are found only in about 20-30% of HCCs, suggesting that the predominant mechanism(s) activating Wnt/FZD signaling pathway may be different from that found in colorectal cancers. There is accumulating evidence to suggest that regulatory mechanisms other than mutations involving beta-catenin or proteins in its destruction complex, many of which involve upstream components of the Wnt/FZD cascade, are important in HCC. Furthermore, information on the target genes of Wnt/FZD signaling and their roles in hepatocarcinogenesis is limited despite the recent discovery of several candidate genes. This review focuses on the alterations of Wnt/FZD signaling pathways and their relationship to the pathogenesis of HCC. A better understanding of the precise mechanisms of altered Wnt/FZD signaling may provide new molecular targets for therapy of HCC.
引用
收藏
页码:1901 / 1915
页数:15
相关论文
共 135 条
[1]   Expression of potential β-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice [J].
Anna, CH ;
Iida, M ;
Sills, RC ;
Devereux, TR .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2003, 190 (02) :135-145
[2]   GSK-3β phosphorylation and alteration of β-catenin in hepatocellular carcinoma [J].
Ban, KC ;
Singh, H ;
Krishnan, R ;
Seow, HF .
CANCER LETTERS, 2003, 199 (02) :201-208
[3]   A new member of the frizzled family from Drosophila functions as a Wingless receptor [J].
Bhanot, P ;
Brink, M ;
Samos, CH ;
Hsieh, JC ;
Wang, YS ;
Macke, JP ;
Andrew, D ;
Nathans, J ;
Nusse, R .
NATURE, 1996, 382 (6588) :225-230
[4]  
Brannon M, 1999, DEVELOPMENT, V126, P3159
[5]   Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize β-catenin independently of Frizzled proteins [J].
Brennan, K ;
Gonzalez-Sancho, JM ;
Castelo-Soccio, LA ;
Howe, LR ;
Brown, AMC .
ONCOGENE, 2004, 23 (28) :4873-4884
[6]   New targets of β-catenin signaling in the liver are involved in the glutamine metabolism [J].
Cadoret, A ;
Ovejero, C ;
Terris, B ;
Souil, E ;
Lévy, L ;
Lamers, WH ;
Kitajewski, J ;
Kahn, A ;
Perret, C .
ONCOGENE, 2002, 21 (54) :8293-8301
[7]  
Cadoret A, 2001, CANCER RES, V61, P3245
[8]   Activation of the canonical Wnt/β-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer [J].
Calvisi, DF ;
Conner, EA ;
Ladu, S ;
Lemmer, ER ;
Factor, VM ;
Thorgeirsson, SS .
JOURNAL OF HEPATOLOGY, 2005, 42 (06) :842-849
[9]   Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells [J].
Cervello, M ;
Giannitrapani, L ;
Labbozzetta, M ;
Notarbartolo, M ;
D'Alessandro, N ;
Lampiasi, N ;
Azzolina, A ;
Montalto, G .
SIGNAL TRANSDUCTION AND COMMUNICATION IN CANCER CELLS, 2004, 1028 :432-439
[10]   High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma [J].
Chan, KL ;
Guan, XY ;
OI-Lin, I .
HUMAN PATHOLOGY, 2004, 35 (11) :1324-1331